MITO – mitochondrial disease
Mitochondrial disease refers to a group of rare genetic disorders that affect our mitochondria, the power plants of our body’s cells.
Mitochondria produce the energy needed for all cells in the body to work properly. They help turn energy from food into energy that cells can use. In children with mitochondrial disease, their mitochondria do not work correctly and not enough energy is made to sustain effective organ function.
Because mitochondria are in virtually every cell, mitochondrial diseases can cause a range of symptoms including hearing loss, seizures, strokes, heart failure, muscle weakness and intellectual disability. Children with mitochondrial disease may have problems in multiple organs.
These baffling, often fatal disorders can be extremely difficult to diagnose. More than 1,200 genes contribute to healthy mitochondria, making it challenging to identify which gene is responsible.
Diagnosis allows children to access tailored care and potentially, clinical trials.
Who does it affect?
Who does it affect?
- Each week one baby is born in Australia with a severe form of mitochondrial disease. This equals about one in every 5,000 births.
- Currently, up to 40 per cent of mitochondrial disease cases go undiagnosed.
- The disease can occur at birth or later in life. Sometimes symptoms can appear suddenly after a stress like a viral illness.
- Sometimes referred to as Mito, mitochondrial disease is often summarised as being able to cause any symptom, in any organ, at any age.
Our mitochondrial research
Our mitochondrial research
Our research aims to diagnose all children with mitochondrial disease to end an often long and painful diagnostic journey. This involves identifying new disease-causing genes and streamlining diagnostic processes.
We are determining how different genes cause the disease and trialling new reproductive options, including mitochondrial donation and potential treatments.
We are researching mitochondrial diseases including:
- Alpers syndrome
- Barth syndrome
- Leigh syndrome
- Lethal infantile mitochondrial disease
- MELAS
- Mitochondrial DNA disorders
- Mitochondrial encephalopathy
- Mitochondrial myopathy
- Crdiomyopathy and cytopathy
- OXPHOS disease
- Respiratory chain disease
- Pyruvate dehydrogenase deficiency
- Sengers syndrome
Impacts of our research
Impacts of our research
- We're leading global efforts to improve the diagnosis of inherited mitochondrial energy generation disorders.
- Pioneering approaches to translate technology to study DNA Next Generation Sequencing (NGS) and cellular protein profiles (proteomics) into genetic diagnosis.
- Using NGS to study mitochondrial disease for 1,200 genes that make mitochondrial proteins.
- Discovering over 30 new disease genes that cause Leigh syndrome and other severe childhood-onset mitochondrial disorders, helping couples who lost children to mitochondrial disease conceive healthy children.
- Led the scientific/medical campaign for the legalisation of mitochondrial donation, a new IVF-based procedure for families at high risk of having a child with severe mitochondrial disease. This resulted in Maeve’s Law being approved by the Australian Parliament in March 2022. We’re now leading the clinical/genomics network for a national trial of mitochondrial donation.
Our vision
Our vision
We are working to better understand what causes mitochondrial disease and how it progresses to help couples access reproductive options and treatments. We also aim to make faster and more accurate genetic diagnosis possible for all families.
Where to next?
Where to next?
We’re using cutting-edge multi-omic technologies including long-read DNA sequencing, RNA sequencing and quantitative proteomics to tackle the most difficult to diagnose cases of mitochondrial disease. We aim to accurately obtain a genetic diagnosis for all children and families without the need for a long diagnostic journey.